Na-ASP-2 Hookworm Vaccine
PreclinicalVaccine
Na-ASP-2 Hookworm Vaccine is one of 5 biologic programs targeting Hookworm Infection. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Skin
#DrugCompanyPhaseTrials
1Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 1
Litifilimab
BiogenPhase 1
Na-ASP-2 Hookworm Vaccine
AAlbert B. Sabin Vaccine Institute
Preclinical
Chlorhexidine-Alcohol
WWashington University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hookworm Infection1 trial
Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Completed·—·N/A·NCT00939198·87 enrolled
Skin1 trial
Development of a Skin Test for the Na-ASP-2 Hookworm Antigen
Completed·—·N/A·NCT00603889·12 enrolled
Phase 11 trial
Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults
Terminated·—·Phase 1·NCT00473967·9 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Na-ASP-2 Hookworm Vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details